News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
841,705 Results
Type
Article (76006)
Company Profile (728)
Press Release (764952)
Multimedia
Podcasts (191)
Webinars (29)
Section
Business (228134)
Career Advice (3742)
Deals (39477)
Drug Delivery (151)
Drug Development (89827)
Employer Resources (205)
FDA (18160)
Job Trends (17233)
News (389368)
Policy (39007)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3015)
Academic (1)
Accelerated approval (35)
Adcomms (36)
Allergies (154)
Alliances (56132)
ALS (183)
Alzheimer's disease (1809)
Antibody-drug conjugate (ADC) (357)
Approvals (18348)
Artificial intelligence (603)
Autoimmune disease (176)
Automation (40)
Bankruptcy (404)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (206)
Biotechnology (448)
Bladder cancer (164)
Brain cancer (66)
Breast cancer (677)
Cancer (5125)
Cardiovascular disease (453)
Career advice (3208)
Career pathing (42)
CAR-T (313)
CDC (59)
Celiac Disease (2)
Cell therapy (833)
Cervical cancer (38)
Clinical research (75962)
Collaboration (1879)
Company closure (4)
Compensation (1195)
Complete response letters (75)
COVID-19 (2995)
CRISPR (101)
C-suite (914)
Cystic fibrosis (155)
Data (6407)
Decentralized trials (2)
Denatured (70)
Depression (152)
Diabetes (540)
Diagnostics (7253)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (288)
Drug pricing (226)
Drug shortages (36)
Duchenne muscular dystrophy (247)
Earnings (97618)
Editorial (67)
Employer branding (25)
Employer resources (174)
Events (134172)
Executive appointments (1048)
FDA (21413)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1581)
Gene editing (220)
Generative AI (57)
Gene therapy (680)
GLP-1 (1145)
Government (5408)
Grass and pollen (8)
Guidances (387)
Healthcare (20939)
HIV (65)
Huntington's disease (50)
IgA nephropathy (88)
Immunology and inflammation (301)
Immuno-oncology (66)
Indications (111)
Infectious disease (3295)
Inflammatory bowel disease (208)
Inflation Reduction Act (17)
Influenza (126)
Intellectual property (257)
Interviews (730)
IPO (17892)
IRA (61)
Job creations (5000)
Job search strategy (2599)
JPM (71)
Kidney cancer (17)
Labor market (96)
Layoffs (656)
Leadership (41)
Legal (9964)
Liver cancer (99)
Longevity (15)
Lung cancer (691)
Lymphoma (387)
Machine learning (44)
Management (66)
Manufacturing (869)
MASH (178)
Medical device (15036)
Medtech (15093)
Mergers & acquisitions (22671)
Metabolic disorders (1432)
Multiple sclerosis (170)
NASH (23)
Neurodegenerative disease (364)
Neuropsychiatric disorders (105)
Neuroscience (3160)
Neurotech (1)
NextGen: Class of 2026 (7658)
Non-profit (5116)
Now hiring (68)
Obesity (699)
Opinion (337)
Ovarian cancer (170)
Pain (219)
Pancreatic cancer (239)
Parkinson's disease (301)
Partnered (36)
Patents (520)
Patient recruitment (514)
Peanut (61)
People (65787)
Pharmaceutical (135)
Pharmacy benefit managers (33)
Phase 1 (23508)
Phase 2 (33110)
Phase 3 (24952)
Pipeline (5446)
Policy (342)
Postmarket research (3258)
Preclinical (10329)
Press Release (72)
Prostate cancer (253)
Psychedelics (58)
Radiopharmaceuticals (304)
Rare diseases (946)
Real estate (7197)
Recruiting (81)
Regulatory (28436)
Reports (68)
Research institute (2728)
Resumes & cover letters (582)
Rett syndrome (28)
RNA editing (21)
RSV (86)
Schizophrenia (162)
Series A (263)
Series B (204)
Service/supplier (26)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (177)
Sponsored (48)
Startups (4243)
State (2)
Stomach cancer (20)
Supply chain (112)
Tariffs (101)
The Weekly (119)
Vaccines (1169)
Venture capital (100)
Weight loss (481)
Women's health (94)
Worklife (22)
Date
Today (36)
Last 7 days (658)
Last 30 days (2263)
Last 365 days (32139)
2026 (3721)
2025 (32545)
2024 (37901)
2023 (42566)
2022 (53927)
2021 (58723)
2020 (57663)
2019 (51301)
2018 (39082)
2017 (36830)
2016 (37740)
2015 (43730)
2014 (38413)
2013 (34388)
2012 (36287)
2011 (36403)
2010 (35834)
Location
Africa (1210)
Alabama (92)
Alaska (7)
Arizona (327)
Arkansas (14)
Asia (50149)
Australia (8599)
California (11774)
Canada (3370)
China (1200)
Colorado (501)
Connecticut (509)
Delaware (352)
Europe (113532)
Florida (1740)
Georgia (378)
Hawaii (4)
Idaho (67)
Illinois (958)
India (72)
Indiana (553)
Iowa (24)
Japan (447)
Kansas (133)
Kentucky (43)
Louisiana (30)
Maine (83)
Maryland (1473)
Massachusetts (8646)
Michigan (358)
Minnesota (673)
Mississippi (6)
Missouri (143)
Montana (36)
Nebraska (29)
Nevada (128)
New Hampshire (85)
New Jersey (3165)
New Mexico (33)
New York (3104)
North Carolina (1630)
North Dakota (10)
Northern California (5668)
Ohio (358)
Oklahoma (23)
Oregon (53)
Pennsylvania (2345)
Puerto Rico (25)
Rhode Island (51)
South America (1577)
South Carolina (68)
South Dakota (1)
Southern California (4552)
Tennessee (179)
Texas (1843)
United States (42329)
Utah (351)
Vermont (1)
Virginia (294)
Washington D.C. (88)
Washington State (984)
West Virginia (4)
Wisconsin (131)
Wyoming (2)
841,705 Results for "jiangsu nhwa pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
Teva Pharmaceutical Investments Singapore Pte Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd. and Jiangsu Nhwa Pharmaceutical Co., Ltd announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease and tardive dyskinesia in adults.
February 26, 2024
·
6 min read
Press Releases
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
January 12, 2026
·
5 min read
Press Releases
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
January 12, 2026
·
3 min read
Press Releases
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
January 19, 2026
·
4 min read
Press Releases
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
February 10, 2026
·
4 min read
Press Releases
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
February 2, 2026
·
7 min read
Press Releases
Driven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the issue of drug gap in Japan
December 15, 2025
·
3 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Business
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China
Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC).
February 7, 2024
·
7 min read
Press Releases
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
January 29, 2026
·
6 min read
1 of 84,171
Next
